SGLT2 inhibitors provide insulin-independent glucose lowering effects by inhibiting glucose reabsorption in the proximal renal tubule, resulting in weight loss and A1C reduction in type 2 diabetes.26 However, the therapeutic use of these medications in T1D has not yet been proposed. The gene discussed is INS; the disease is type 1 diabetes mellitus.